BEAM
insider transactionsBeam Therapeutics Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-229.6K
0 buy · 229.6K sell
Net value · 365d
-$6.3M
$0 in · $6.3M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
20
0 buy · 229.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
19.7K sh
Own New
-
Grant·A
Director
$0
19.7K sh
Own New
-
Grant·A
Director
$0
19.7K sh
Own New
-
Grant·A
Director
$0
19.7K sh
Own New
-
Grant·A
Director
$0
19.7K sh
Own New
-
Grant·A
Director
$0
19.7K sh
Own New
-
Sell·S
John M. Evans KEY
CEO · 10b5-1
$739.3K
30.1K sh · $24.58
Own -3%
-
Sell·S
Chief Medical Officer · 10b5-1
$164.7K
6.7K sh · $24.58
Own -6%
-
Sell·S
SVP, Finance and Treasurer · 10b5-1
$79.7K
3.2K sh · $24.58
Own -6%
-
Sell·S
Chief Legal Officer · 10b5-1
$146.4K
6.0K sh · $24.58
Own -5%
-
Sell·S
President · 10b5-1
$290.3K
11.8K sh · $24.58
Own -5%
-
Exercise·M
John M. Evans KEY
CEO · 10b5-1
$0
25.0K sh
Own New
-
Grant·A
John M. Evans KEY
CEO · 10b5-1
$0
90.0K sh
Own +9%
-
Sell·S
John M. Evans KEY
CEO · 10b5-1
$569.1K
25.0K sh · $22.76
Own -2%
-
Exercise·M
John M. Evans KEY
CEO · 10b5-1
$16.8K
25.0K sh · $0.67
Own +3%
-
Grant·A
Chief Legal Officer
$0
20.0K sh
Own +21%
-
Grant·A
SVP, Finance and Treasurer
$0
20.0K sh
Own +57%
-
Grant·A
Chief Medical Officer
$0
31.8K sh
Own +41%
-
Grant·A
Chief Financial Officer
$0
31.8K sh
Own +43%
-
Grant·A
President
$0
40.0K sh
Own +21%
-
Exercise·M
John M. Evans KEY
CEO · 10b5-1
$0
25.0K sh
Own +134%
-
Sell·S
John M. Evans KEY
CEO · 10b5-1
$559.2K
25.0K sh · $22.37
Own -2%
-
Exercise·M
John M. Evans KEY
CEO · 10b5-1
$16.8K
25.0K sh · $0.67
Own +3%
-
Exercise·M
President · 10b5-1
$0
35.0K sh
Own +10%
-
Sell·S
President · 10b5-1
$1.1M
35.0K sh · $32.00
Own -16%
-
Exercise·M
President · 10b5-1
$595.0K
35.0K sh · $17.00
Own +18%
-
Grant·A
President
$0
80.0K sh
Own New
-
Grant·A
SVP, Finance and Treasurer
$0
40.0K sh
Own New
-
Grant·A
Chief Financial Officer
$0
63.5K sh
Own New
-
Grant·A
Chief Legal Officer
$0
40.0K sh
Own New
-
Grant·A
John M. Evans KEY
CEO · 10b5-1
$0
180.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
88.5K sh
Own New
-
Exercise·M
John M. Evans KEY
CEO · 10b5-1
$0
25.0K sh
Own +57%
-
Sell·S
John M. Evans KEY
CEO · 10b5-1
$84.3K
2.9K sh · $29.00
Own -0%
-
Sell·S
John M. Evans KEY
CEO · 10b5-1
$624.7K
22.1K sh · $28.27
Own -2%
-
Exercise·M
John M. Evans KEY
CEO · 10b5-1
$16.8K
25.0K sh · $0.67
Own +3%
-
Exercise·M
John M. Evans KEY
CEO · 10b5-1
$0
5.7K sh
Own +6%
-
Exercise·M
John M. Evans KEY
CEO · 10b5-1
$0
19.3K sh
Own New
-
Sell·S
John M. Evans KEY
CEO · 10b5-1
$257.8K
8.7K sh · $29.74
Own -1%
-
Sell·S
John M. Evans KEY
CEO · 10b5-1
$476.8K
16.3K sh · $29.19
Own -2%
-
Exercise·M
John M. Evans KEY
CEO · 10b5-1
$3.8K
5.7K sh · $0.67
Own +1%
-
Exercise·M
John M. Evans KEY
CEO · 10b5-1
$13.0K
19.3K sh · $0.67
Own +2%
-
Sell·S
SVP, Finance and Treasurer · 10b5-1
$216.9K
6.2K sh · $35.00
Own -15%
-
Sell·S
Chief Legal Officer · 10b5-1
$46.6K
1.4K sh · $34.00
Own -1%
-
Sell·S
SVP, Finance and Treasurer · 10b5-1
$91.4K
3.0K sh · $30.12
Own -7%
-
Sell·S
Chief Legal Officer · 10b5-1
$19.8K
559 sh · $35.40
Own -1%
-
Sell·S
Chief Legal Officer · 10b5-1
$554.1K
16.0K sh · $34.72
Own -14%
-
Sell·S
Chief Legal Officer · 10b5-1
$71.0K
2.1K sh · $33.62
Own -2%
-
Sell·S
Chief Financial Officer · 10b5-1
$170.6K
6.3K sh · $27.10
Own -8%
-
Sell·S
Chief Legal Officer · 10b5-1
$34.0K
1.3K sh · $27.10
Own -1%
-
Grant·A
Chief Medical Officer
$0
12.5K sh
Own +19%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 3, 2026 | Mark Fishman | Grant A | 19.7K | $0 |
| Jun 3, 2026 | Chirfi Guindo | Grant A | 19.7K | $0 |
| Jun 3, 2026 | Christi Shaw | Grant A | 19.7K | $0 |
| Jun 3, 2026 | Kathleen E Walsh | Grant A | 19.7K | $0 |
| Jun 3, 2026 | John Maraganore | Grant A | 19.7K | $0 |
| Jun 3, 2026 | Graham K Cooper | Grant A | 19.7K | $0 |
| Apr 1, 2026 | John M. Evans KEY 10b5-1 | Sell S | 30.1K | $739.3K |
| Apr 1, 2026 | Amy Simon 10b5-1 | Sell S | 6.7K | $164.7K |
| Apr 1, 2026 | Bethany J Cavanagh 10b5-1 | Sell S | 3.2K | $79.7K |
| Apr 1, 2026 | Christine Bellon 10b5-1 | Sell S | 6.0K | $146.4K |
| Apr 1, 2026 | Giuseppe Ciaramella KEY 10b5-1 | Sell S | 11.8K | $290.3K |
| Mar 31, 2026 | John M. Evans KEY 10b5-1 | Exercise M | 25.0K | $0 |
| Mar 31, 2026 | John M. Evans KEY 10b5-1 | Grant A | 90.0K | $0 |
| Mar 31, 2026 | John M. Evans KEY 10b5-1 | Sell S | 25.0K | $569.1K |
| Mar 31, 2026 | John M. Evans KEY 10b5-1 | Exercise M | 25.0K | $16.8K |
| Mar 31, 2026 | Christine Bellon | Grant A | 20.0K | $0 |
| Mar 31, 2026 | Bethany J Cavanagh | Grant A | 20.0K | $0 |
| Mar 31, 2026 | Amy Simon | Grant A | 31.8K | $0 |
| Mar 31, 2026 | Sravan Kumar Emany KEY | Grant A | 31.8K | $0 |
| Mar 31, 2026 | Giuseppe Ciaramella KEY | Grant A | 40.0K | $0 |
| Mar 30, 2026 | John M. Evans KEY 10b5-1 | Exercise M | 25.0K | $0 |
| Mar 30, 2026 | John M. Evans KEY 10b5-1 | Sell S | 25.0K | $559.2K |
| Mar 30, 2026 | John M. Evans KEY 10b5-1 | Exercise M | 25.0K | $16.8K |
| Feb 24, 2026 | Giuseppe Ciaramella KEY 10b5-1 | Exercise M | 35.0K | $0 |
| Feb 24, 2026 | Giuseppe Ciaramella KEY 10b5-1 | Sell S | 35.0K | $1.1M |
| Feb 24, 2026 | Giuseppe Ciaramella KEY 10b5-1 | Exercise M | 35.0K | $595.0K |
| Jan 31, 2026 | Giuseppe Ciaramella KEY | Grant A | 80.0K | $0 |
| Jan 31, 2026 | Bethany J Cavanagh | Grant A | 40.0K | $0 |
| Jan 31, 2026 | Sravan Kumar Emany KEY | Grant A | 63.5K | $0 |
| Jan 31, 2026 | Christine Bellon | Grant A | 40.0K | $0 |
| Jan 31, 2026 | John M. Evans KEY 10b5-1 | Grant A | 180.0K | $0 |
| Jan 31, 2026 | Amy Simon | Grant A | 88.5K | $0 |
| Jan 30, 2026 | John M. Evans KEY 10b5-1 | Exercise M | 25.0K | $0 |
| Jan 30, 2026 | John M. Evans KEY 10b5-1 | Sell S | 2.9K | $84.3K |
| Jan 30, 2026 | John M. Evans KEY 10b5-1 | Sell S | 22.1K | $624.7K |
| Jan 30, 2026 | John M. Evans KEY 10b5-1 | Exercise M | 25.0K | $16.8K |
| Jan 29, 2026 | John M. Evans KEY 10b5-1 | Exercise M | 5.7K | $0 |
| Jan 29, 2026 | John M. Evans KEY 10b5-1 | Exercise M | 19.3K | $0 |
| Jan 29, 2026 | John M. Evans KEY 10b5-1 | Sell S | 8.7K | $257.8K |
| Jan 29, 2026 | John M. Evans KEY 10b5-1 | Sell S | 16.3K | $476.8K |
| Jan 29, 2026 | John M. Evans KEY 10b5-1 | Exercise M | 5.7K | $3.8K |
| Jan 29, 2026 | John M. Evans KEY 10b5-1 | Exercise M | 19.3K | $13.0K |
| Jan 22, 2026 | Bethany J Cavanagh 10b5-1 | Sell S | 6.2K | $216.9K |
| Jan 22, 2026 | Christine Bellon 10b5-1 | Sell S | 1.4K | $46.6K |
| Jan 20, 2026 | Bethany J Cavanagh 10b5-1 | Sell S | 3.0K | $91.4K |
| Jan 15, 2026 | Christine Bellon 10b5-1 | Sell S | 559 | $19.8K |
| Jan 15, 2026 | Christine Bellon 10b5-1 | Sell S | 16.0K | $554.1K |
| Jan 15, 2026 | Christine Bellon 10b5-1 | Sell S | 2.1K | $71.0K |
| Dec 31, 2025 | Sravan Kumar Emany KEY 10b5-1 | Sell S | 6.3K | $170.6K |
| Dec 31, 2025 | Christine Bellon 10b5-1 | Sell S | 1.3K | $34.0K |
| Dec 31, 2025 | Amy Simon | Grant A | 12.5K | $0 |
About BEAM insider trading
This page tracks insider transactions for Beam Therapeutics Inc. (BEAM) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.